155 related articles for article (PubMed ID: 23540777)
1. Perioperative chemotherapy: when to use it, what to use, and why.
Johnson DC; Pruthi RS; Woods ME
Urol Clin North Am; 2013 May; 40(2):183-95. PubMed ID: 23540777
[TBL] [Abstract][Full Text] [Related]
2. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
3. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.
Gontero P; Marini L; Frea B
BJU Int; 2005 Nov; 96(7):970-6. PubMed ID: 16225511
[No Abstract] [Full Text] [Related]
4. Editorial comment.
Berglund RK
Urology; 2009 Nov; 74(5):1083; author reply 1084. PubMed ID: 19883829
[No Abstract] [Full Text] [Related]
5. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine in bladder cancer.
El Karak F; Flechon A
Expert Opin Pharmacother; 2007 Dec; 8(18):3251-6. PubMed ID: 18035967
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Cao M; Ma CK; Ma J; Chen HG; Xue W
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):385-7. PubMed ID: 21875472
[TBL] [Abstract][Full Text] [Related]
8. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation.
De Berardinis E; Antonini G; Peters GJ; Loves WJ; Van der Born K; Codacci-Pisanelli G; Di Silverio F
BJU Int; 2004 Mar; 93(4):491-4. PubMed ID: 15008715
[TBL] [Abstract][Full Text] [Related]
9. Combination Intravesical Therapy.
Brooks NA; O'Donnell MA
Urol Clin North Am; 2020 Feb; 47(1):83-91. PubMed ID: 31757303
[TBL] [Abstract][Full Text] [Related]
10. Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer.
Maffezzini M; Campodonico F; Puntoni M; Martelli A; Mattioli F
Urology; 2009 Nov; 74(5):1078-83. PubMed ID: 19773039
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer.
Campodonico F; Mattioli F; Manfredi V; Capponi G; Pasquini P; Martelli A; Maffezzini M
Anticancer Res; 2007; 27(2):1179-83. PubMed ID: 17465260
[TBL] [Abstract][Full Text] [Related]
12. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study.
Mattioli F; Curotto A; Manfredi V; Gosmar M; Garbero C; Ambruosi C; Carmignani G; Martelli A
Anticancer Res; 2005; 25(3c):2493-6. PubMed ID: 16080482
[TBL] [Abstract][Full Text] [Related]
13. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability.
Campodonico F; Canepa G; Capponi G; Bozzo L; Maffezzini M
Anticancer Res; 2005; 25(3c):2381-4. PubMed ID: 16080464
[TBL] [Abstract][Full Text] [Related]
14. Intravesical therapy for superficial cancer: need for more options.
Crawford ED
J Clin Oncol; 2002 Aug; 20(15):3185-6. PubMed ID: 12149286
[No Abstract] [Full Text] [Related]
15. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder.
Campodonico F; Maffezzini M
Urology; 2005 Nov; 66(5):1141-2; author reply 1142. PubMed ID: 16286156
[No Abstract] [Full Text] [Related]
16. Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer.
Grimberg DC; Shah A; Inman BA
Eur Urol Focus; 2020 Jul; 6(4):620-622. PubMed ID: 31561993
[TBL] [Abstract][Full Text] [Related]
17. Combined systemic therapy and radiotherapy for bladder cancer.
Rödel C; Weiss C; Sauer R
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():29-31. PubMed ID: 18167005
[No Abstract] [Full Text] [Related]
18. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
[TBL] [Abstract][Full Text] [Related]
19. Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review.
Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
Investig Clin Urol; 2021 Nov; 62(6):623-630. PubMed ID: 34729962
[TBL] [Abstract][Full Text] [Related]
20. Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial.
Li R; Li Y; Song J; Gao K; Chen K; Yang X; Ding Y; Ma X; Wang Y; Li W; Wang Y; Wang Z; Dong Z
BMC Urol; 2020 Jul; 20(1):97. PubMed ID: 32660456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]